BIODEXA PHARMA ADR O.N. Aktie

Biodexa will propose a reorganization of its share capital at the annual general meeting on June 17, 2026, which foresees a 10,000:1 share consolidation and would reduce the number of ordinary shares to 37,305,681. Each consolidated ordinary share would be split into one new ordinary share and 9,999 deferred E-shares with limited rights. The ADS exchange ratio would change from 500,000:1 to 50:1, while the number of outstanding ADS (746,113) would remain unchanged; the change is to take effect on June 18, 2026 if approved. The company says the move is intended to simplify the capital structure; Biodexa is in the clinical phase and has a market capitalization of about US$2.41 million. » More on de.investing.com

Biodexa has commissioned Syngene to manufacture the active ingredient and formulation of MTX240 for clinical trials. MTX240, licensed by Biodexa from Otsuka, targets GIST and acts by bringing together PDE3A and SLFN12 through a KIT-independent cell death mechanism. Biodexa plans to file an IND and start a phase 1b/2a dose‑escalation study with an expansion phase in TKI-resistant GIST later this year. Biodexa's shares trade near their 52-week low and fell about 96% last year. » More on de.investing.com

Biodexa will change the ADR ratio on April 6, 2026, from one ADR representing 100,000 common shares to one ADR representing 500,000 common shares; ADR holders must exchange five old ADRs for one new ADR. The new ADRs will receive CUSIP 59564R872, the old ADRs carry CUSIP 59564R880; fractional interests will be sold and proceeds distributed. The underlying common shares remain unchanged; the measure is intended to align the ADR price with NASDAQ’s minimum $1.00 requirement, but does not guarantee compliance. » More on de.investing.com